Epinephrine (Epinephrine) Patent Expiration, LOE Window & CMS Spending
Epinephrine (Epinephrine) by Bpi Labs: FDA Orange Book LOE 2045-01-17, 1 AB generics, $382.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bpi Labs |
| FDA Application & Pathway | N205029 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2045-01-17 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $382.0M |
| 2024 Medicare Part D Spend | $119.3M |
| 2024 Medicaid Spend | $262.7M |
| Reported Wholesale Price Change (CA SB 17) | 5 WAC filings (max 77.2% 2-yr change) |